ar-9281 and Insulin-Resistance

ar-9281 has been researched along with Insulin-Resistance* in 1 studies

Other Studies

1 other study(ies) available for ar-9281 and Insulin-Resistance

Article	Year
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia. Bioorganic & medicinal chemistry letters, 2011, Feb-01, Volume: 21, Issue:3 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse model of diet induced obesity, AR9281 attenuated the enhanced glucose excursion following an intraperitoneal glucose tolerance test. AR9281 also attenuated the increase in blood pressure in angiotensin-II-induced hypertension in rats. These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the observed pharmacology in rodents. Topics: Adamantane; Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Glucose; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Hypertension; Insulin Resistance; Mice; Obesity; Rats; Urea	2011

Article

Year

1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia.

Bioorganic & medicinal chemistry letters, 2011, Feb-01, Volume: 21, Issue:3

1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse model of diet induced obesity, AR9281 attenuated the enhanced glucose excursion following an intraperitoneal glucose tolerance test. AR9281 also attenuated the increase in blood pressure in angiotensin-II-induced hypertension in rats. These effects were dose-dependent and well correlated with inhibition of the sEH activity in whole blood, consistent with a role of sEH in the observed pharmacology in rodents.

Topics: Adamantane; Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Blood Glucose; Disease Models, Animal; Enzyme Inhibitors; Epoxide Hydrolases; Hypertension; Insulin Resistance; Mice; Obesity; Rats; Urea

2011